Pacific Biosciences Stock Surges on Major Regulatory Win in China

Pacific Biosciences shares are demonstrating significant momentum in today’s trading session, propelled by a landmark regulatory achievement in China that has overshadowed mixed quarterly earnings results. The biotechnology firm reported revenue that fell short of projections but impressed investors with improved profitability metrics and record-breaking consumables sales.

In a pivotal development on November 4, 2025, Pacific Biosciences received Class III medical device approval in China for its Sequel II CNDx System. This authorization represents the world’s first regulatory clearance for a clinical long-read sequencer, positioning the company to capitalize on China’s vast precision medicine sector.

The clinical implications of this milestone are substantial. Medical facilities across Read more...